Integrative Endocrinology and Hormone Optimization Explained

Integrative Endocrinology and Hormone Optimization

Abstract

In this educational post, I guide you through a practical, clinician-focused journey into endocrine optimization with a clear emphasis on sex hormone-binding globulin (SHBG), polycystic ovary syndrome (PCOS), prostate-specific antigen (PSA) interpretation, and dehydroepiandrosterone (DHEA). I explain the physiology that drives symptoms, the lab markers that predict risk, and the therapeutic strategies that correct root causes. Drawing from modern, evidence-based research and integrative practice, I show how integrative chiropractic care complements metabolic and hormonal therapies—optimizing neuromusculoskeletal function, autonomic balance, and lifestyle execution. You will learn why we do not automatically try to lower SHBG, how insulin resistance underpins many endocrine patterns, how to recognize atypical PCOS presentations, how to integrate GLP-1 strategies and spironolactone responsibly, why free PSA and PSA velocity shape prostate decision-making, and how DHEA influences neuroendocrine function, libido, and well-being. I include clinical observations from my practice and share insights across my professional platforms to connect research to real-world outcomes.

Hormone Transport Fundamentals: Why SHBG Matters More Than Most Think

When I evaluate hormone-related symptoms, I start with the fundamentals of hormone transport and receptor dynamics. Sex hormone-binding globulin (SHBG) is a major carrier protein that binds androgens and estrogens in circulation, delivering them to tissues and regulating the free fraction available to bind intracellular receptors (Hammond, 2016). Because SHBG has a higher affinity for androgens—particularly testosterone—it shapes how much testosterone remains free and bioavailable.

• Key physiological points
  • Bound vs. free hormone: Only the free fraction is immediately biologically active; however, the bound reservoir contributes to hormone delivery and tissue equilibrium (Hammond, 2016).
  • Receptor occupancy: Hormones exert their effects after crossing cell membranes and binding to receptors; adequate total hormone levels are often required to saturate binding proteins and receptors, ensuring sufficient free hormone reaches target tissues.
  • SHBG and androgens: Higher SHBG preferentially binds androgens, potentially lowering free testosterone even when total testosterone appears normal.

In my practice, I frequently see scenarios where a person has a low total testosterone and high SHBG, with symptoms of androgen deficiency. The reflexive impulse to “lower SHBG” is common—but hazardous.

• Why I do not aim to lower SHBG
  • Lower SHBG is consistently associated with insulin resistance, metabolic syndrome, type 2 diabetes, and cardiometabolic risk (Ding et al., 2009; Selva et al., 2007; Lakshman et al., 2010).
  • In many cohorts, low SHBG precedes abnormal A1c, making SHBG a predictive metabolic marker (Ding et al., 2009).
  • Pharmacologically lowering SHBG often implies raising insulin or exogenous estrogen—neither is an appropriate metabolic strategy for risk reduction.

Instead, I target the root drivers of SHBG fluctuations—primarily insulin and hepatic regulation—and then optimize total testosterone to saturate carriers and receptors so an adequate free fraction remains.

• Clinical approach
  • Address insulin resistance and hepatic health through nutrition, exercise, and, when appropriate, metformin or GLP-1 receptor agonists (Lean et al., 2019).
  • Optimize total testosterone within safe, individualized ranges to ensure adequate receptor occupancy and symptomatic relief.
  • Consider botanicals and nutraceuticals that support androgen bioavailability; some patients report benefit with Shilajit, though I prioritize evidence-backed strategies tied to cardiometabolic parameters and symptom tracking (Pandit et al., 2016).

Integrative chiropractic care supports this process by improving autonomic balance, sleep quality, and pain modulation, all of which reduce allostatic load and improve insulin sensitivity (Pickering et al., 2017). In patients with chronic pain and sleep disruption, targeted manual interventions and movement prescriptions help normalize cortisol rhythms and lower systemic inflammation, indirectly supporting healthier SHBG dynamics and androgen signaling.

SHBG, Insulin Resistance, and Metabolic Risk: Reading the Pattern

In individuals, low SHBG signals trouble. Large studies demonstrate that individuals with low SHBG have a higher risk for type 2 diabetes, independent of BMI (Ding et al., 2009). In women—particularly those with PCOS—low SHBG aligns with hyperinsulinemia, hyperandrogenism, and metabolic dysfunction (Goodarzi et al., 2011).

• Clinical implications
  • If SHBG is low and symptoms suggest androgen excess or deficiency, I reflexively assess fasting insulin, HOMA-IR, A1c, lipids, ALT/AST, and hs-CRP.
  • A falling SHBG over time can be an early red flag for worsening insulin resistance long before glucose control markers breach reference ranges.
  • In women with PCOS, low SHBG correlates with higher free testosterone, dermal androgenicity, and ovulatory dysfunction.
• Therapeutic rationale
  • Raising SHBG by improving insulin sensitivity reduces free androgen spillover, which drives acne, hirsutism, and menstrual irregularity.
  • Lifestyle and pharmacologic strategies that lower insulin—such as calorie-appropriate, protein-forward, anti-inflammatory nutrition, resistance training, time-restricted feeding, metformin, or GLP-1 RAs—produce sustained benefits across endocrine and metabolic axes (Lean et al., 2019; Jensterle et al., 2015).

This is precisely where integrative chiropractic care fits. Postural correction, mobility restoration, and neuromuscular re-education facilitate consistent exercise adherence and higher training intensity with lower injury risk. My team and I use graded movement planning, spinal stabilization, and soft-tissue strategies to enable patients to sustain resistance training that shifts insulin signaling and body composition—often the decisive factor in SHBG normalization and symptom reversal. I discuss these clinical applications frequently in my practice updates and case reflections on PushAsRx and LinkedIn.

Modern PCOS: Beyond the Stereotypes, Toward Phenotype-Specific Care

Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders in reproductive-age women, but its presentation is varied. Not all patients present with obesity, acne, or hirsutism. Some are lean, athletic, and primarily struggle with cycle irregularity or fertility. The Rotterdam criteria require two of the following three: oligo- or anovulation, hyperandrogenism (clinical or biochemical), and polycystic ovarian morphology on ultrasound (Rotterdam ESHRE/ASRM, 2004).

• Hormonal patterns
  • Many patients have an elevated LH: FSH ratio (>2:1), though not universally.
  • SHBG is often low; free testosterone is elevated despite normal total testosterone.
  • DHEA-S can be high, reflecting adrenal contribution to hyperandrogenism.
  • Insulin resistance is common—even in lean phenotypes—and often precedes overt hyperglycemia (Goodarzi et al., 2011).
• Atypical presentations I encounter
  • Lean, high-performing athletes with irregular or painful menses, normal total testosterone, but free testosterone elevated, and LH > FSH.
  • Primary complaint of dysmenorrhea, with labs showing biochemical hyperandrogenism and low-normal SHBG.
  • Predominant fertility issues without classic dermatologic features.

In such cases, I recommend adding LH and FSH for premenopausal women with cycle complaints, along with free and total testosterone, SHBG, DHEA-S, and insulin metrics. I also assess the gut because dysbiosis contributes to insulin resistance and androgen excess through endotoxemia, shifts in bile acid metabolism, and short-chain fatty acid dynamics (Qi et al., 2019).

• Root-cause therapeutic priorities
  • Nutrition: anti-inflammatory, fiber-rich, protein-adequate; manage glycemic load.
  • Insulin sensitization: gradual titration of metformin up to 2,000–2,100 mg/day as tolerated; GI side effects are dose and sensitivity-dependent and often subside (Podfigurna-Stopa et al., 2016).
  • GLP-1 receptor agonists (e.g., semaglutide, liraglutide) can provide appetite regulation, weight reduction, and improvements in insulin; they frequently restore ovulatory cycles over months (Jensterle et al., 2015).
  • Androgen symptom modulation: spironolactone for hirsutism/acne (typically 50–100 mg/day) while addressing the metabolic drivers; time to effect is usually 6–12 months (Martin et al., 2018).
  • Contraceptive strategies when pregnancy is not desired: combined oral contraceptives with anti-androgenic progestins (e.g., drospirenone) can reduce androgenic symptoms; they often raise SHBG, thereby lowering free testosterone (Landay et al., 2009).
• Fertility trajectory
  • Cycle normalization can take 12–24 months of consistent insulin-focused care.
  • As insulin improves and SHBG rises, LH pulsatility and ovulation typically stabilize, improving fertility outcomes.

Integrative chiropractic care amplifies adherence to these long horizons. By decreasing pain, improving sleep, and enhancing vagal tone, patients engage more reliably with exercise, meal prep, and stress-regulation practices—cumulatively restoring hypothalamic–pituitary–ovarian (HPO) axis regularity. My clinical systems emphasize progressive loading, pelvic and lumbopelvic mechanics, and breathwork to reduce pelvic floor hypertonicity and dysmenorrhea-associated tension, commonly reported by patients at PushAsRx.

• Clinical vignette reflection
  • A tall, athletic 20-something presented primarily with severe dysmenorrhea and cycle irregularity, minimal dermatologic signs, and labs notable for LH > FSH (nearly 3:1), free testosterone elevated, low-normal SHBG, and high DHEA-S. Gut evaluation identified dysbiosis. A phased plan with nutrition, metformin uptitration, targeted probiotics, and structured resistance training plus soft-tissue and spinal mobilization improved symptom burden and cycle regularity over several months. This atypical PCOS phenotype underscores why we must look beyond body composition and acne to identify the pattern.
• Caution with testosterone therapy in PCOS-phenotype
  • With low SHBG, even modest androgen dosing can overshoot free testosterone and drive side effects. I start low and go slow with any androgen support in women who present with or have a history suggestive of PCOS, titrating carefully and monitoring free T, SHBG, and symptoms.

From Androgen Blockade to Metabolic Repair: Why We Choose Each Tool

Treatments like spironolactone and COCs alleviate symptoms by reducing androgen receptor activation or increasing SHBG. However, they do not resolve the metabolic root.

• Why use spironolactone
  • It is an androgen receptor antagonist that reduces hirsutism and acne while upstream metabolic work proceeds (Martin et al., 2018).
  • I monitor potassium and blood pressure, counsel on teratogenic risk (ensure contraception), and set expectations: cosmetic endpoints can take 6–12 months.
• Why use metformin
  • Improves hepatic gluconeogenesis, peripheral glucose uptake, and possibly gut microbiome composition—raising SHBG and lowering free androgens over time (Podfigurna-Stopa et al., 2016).
  • Titration strategy reduces GI side effects: start 500 mg nightly, gradually increase toward 2,000–2,100 mg/day as tolerated.
• Why consider GLP-1 RAs
  • Enhance glucose-dependent insulin secretion, slow gastric emptying, and reduce appetite; clinical trials in PCOS have demonstrated weight loss, improved insulin sensitivity, and menstrual regularity (Jensterle et al., 2015; Lean et al., 2019).
• Lifestyle first, always
  • The most impactful variable across cases remains sustainable nutrition and resistance training. Integrative chiropractic teams help patients move without pain, keep schedules, and regulate stress to maintain these keystone behaviors.

PSA, Free PSA, and Velocity: Smarter Prostate Screening in Androgen Care

In men being considered for androgen optimization, prostate screening must be precise. Total PSA alone lacks sensitivity; combining total PSA, percent free PSA, and PSA velocity improves risk stratification (Thompson et al., 2004; Catalona et al., 1998).

• Key physiology
  • PSA circulates in different forms; the percent free PSA is the proportion unbound by carrier proteins.
  • An inverse relationship exists: a lower percentage of free PSA at a given total PSA level signals higher cancer risk (Catalona et al., 1998).
• Clinical thresholds I use
  • If total PSA is > 4.0 ng/mL, reflex percent free PSA is automatically helpful:
    • <10% free PSA: high likelihood of cancer—refer to urology or obtain a 3T multiparametric prostate MRI.
    • 10–20% free PSA: gray zone—if prostatitis symptoms exist, treat and retest in ~3 months; persistently low free PSA warrants advanced imaging or specialty referral.
    • >20% free PSA: lower likelihood; recheck in 3 months.
  • PSA velocity: a rise of> 0.75–2.0 ng/mL/year (context-dependent) is concerning for aggressive pathology and prompts earlier imaging or referral (Carter et al., 1992; Loeb et al., 2007).
• Important caveats
  • Finasteride reduces total PSA by ~50% but does not alter percent free PSA; adjust interpretation accordingly (Thompson et al., 2003).
  • Recent ejaculation, DRE, cycling, or infection can transiently elevate PSA; percent free PSA is relatively robust to these factors (Eskew et al., 1997).
  • Many men prefer MRI before biopsy; 3T multiparametric MRI has become a valuable, noninvasive triage tool for suspicious PSA patterns (Ahmed et al., 2017).
• Androgen therapy timing
  • I initiate or continue testosterone therapy when PSA is normal and stable and lower urinary tract symptoms do not suggest significant BPH; if PSA is rising or percent free PSA suggests risk, I pause and investigate before proceeding. The androgen saturation model decreases concern for accelerating prostate cancer with physiologic testosterone, but I always integrate urology input when uncertainty exists (Morgentaler & Traish, 2009).

Integrative chiropractic’s role is indirect but meaningful: symptom relief for pelvic and low back pain reduces anxiety, improves sleep, and supports adherence to follow-up and imaging. That adherence is often the difference between reassurance and delayed diagnosis.

DHEA: Neurosteroid Physiology, Sexual Function, and Clinical Dosing

Dehydroepiandrosterone (DHEA) and its sulfated form DHEA-S originate from the adrenal cortex and function as neurosteroids synthesized in the CNS. Levels peak in early adulthood and decline steadily with age (Rainey et al., 2002).

• Why DHEA matters
  • DHEA engages independent CNS receptors and modulates mood, motivation, and sexual function (Maninger et al., 2009).
  • In women, DHEA metabolism can preferentially convert toward DHT and estrogens in tissue-specific ways, affecting libido and orgasmic function, even when testosterone is within target ranges (Arlt et al., 1999).
  • Low DHEA/DHEA-S is associated with declines in bone health, skin integrity, immune function, and possible increases in all-cause mortality, though causality remains under investigation (Shufelt et al., 2010).
• When I consider DHEA
  • Persistent low libido, anhedonia, or fatigue despite optimized thyroid and sex steroids.
  • DHEA-S in double digits (ng/mL) or clearly below lab-specific midlife targets, with corroborating symptoms.
  • Not in PCOS patients with elevated baseline DHEA-S, since excess can worsen androgenic symptoms.
• Dosing strategy
  • I prefer compounded, pharmaceutical-grade DHEA due to variability in OTC supplements.
  • Typical starting doses:
    • Women: 5–10 mg/day, titrating based on DHEA-S and symptoms.
    • Men: 10–25 mg/day, limited by erythrocytosis risk, acne, and alterations in lipid panels.
  • Recheck labs in 6–8 weeks; monitor for acne, hair shedding, mood changes, and sleep effects.
• Why DHEA helps when testosterone is “normal.”
  • DHEA exerts CNS-specific effects that testosterone does not fully replicate.
  • Central neurosteroid signaling aligns more closely with subjective libido and vitality in some patients than peripheral androgen metrics.

Integrative chiropractic care supports DHEA’s potential benefits by normalizing sleep architecture, reducing pain catastrophizing, and encouraging autonomic balance—conditions that enable neurosteroids to exert their effects. In my clinic, when we pair precise endocrine adjustments with spinal and soft-tissue care, patients frequently report disproportionate improvements in overall well-being compared with hormone changes alone.

The Gut–Endocrine Axis: Why We Always Look at the Microbiome

Multiple lines of research now support a gut–ovary–adrenal axis in PCOS and a gut–liver axis in SHBG regulation. Dysbiosis and endotoxemia propagate insulin resistance, driving lower SHBG and higher free androgens; bile acid signaling and short-chain fatty acids also modulate GLP-1 and insulin dynamics (Qi et al., 2019; He & Shi, 2020).

• What I test and why
  • Stool microbiome assessments in moderate-severity PCOS or persistent metabolic dysregulation help identify dysbiosis, pathobionts, and low short-chain fatty acid profiles.
  • Interventions include prebiotic fibers, polyphenol-rich foods, targeted probiotics, and anti-inflammatory dietary patterns.
  • Outcomes I track: postprandial glucose, fasting insulin, SHBG, free testosterone, and cycle regularity.
• Integrative chiropractic synergy
  • We incorporate movement prescriptions that stimulate myokines, improve insulin sensitivity, and favorably alter the gut microbiome. When combined with spinal mobilization and neuromuscular coordination, patients tolerate training volumes that sustain metabolic changes.

Practical Lab Navigation: Putting It All Together

When I suspect metabolic–endocrine interplay, I order an integrated lab panel:

• Baseline endocrine
  • Total and free testosterone, SHBG
  • DHEA-S
  • Estradiol, progesterone (women; cycle-timed), LH, FSH
  • TSH, free T4, free T3 (thyroid–ovary crosstalk matters)
• Metabolic
  • Fasting insulin, glucose, HOMA-IR
  • A1c, lipid panel
  • ALT/AST, GGT
  • hs-CRP
• Men’s prostate
  • PSA with reflex percent free PSA
  • Trend PSA velocity year-over-year
• Gut
  • Stool analysis when symptoms or metabolic resistance persist

I educate patients that SHBG trends can be an earlier metabolic signpost than A1c. If SHBG is low, I intensify insulin-sensitizing strategies. If SHBG is high and the patient is symptomatic for low androgens, I optimize total testosterone and ensure adequate receptor engagement rather than trying to drive SHBG down.

Why Integrative Chiropractic Care Belongs in Endocrine Optimization

Endocrine recovery depends on execution: consistent training, dietary adherence, stress regulation, and sleep. Integrative chiropractic care improves the human performance environment in which hormones function.

• Mechanisms of support
  • Reduce nociceptive input and improve spinal mechanics, lowering sympathetic arousal that disrupts insulin signaling.
  • Implement graded resistance-training progressions and mobility plans that patients can safely sustain.
  • Coach breathing and posture to enhance vagal tone and sleep quality—critical for GH, gonadal steroids, and insulin sensitivity.

Across cases documented in my clinic and in professional updates, combining precise hormone care with musculoskeletal optimization yields faster, more durable symptom improvement than either approach alone.

Patient-Centered Pearls from Clinic

• If SHBG is low and the patient is symptomatic, think insulin first, not “SHBG suppression.”
• In women with PCOS phenotype, start low androgen doses if indicated and track free T and SHBG closely.
• Spironolactone is for symptom control; metabolic repair is for disease modification.
• Expect 12–24 months for full ovulatory restoration in PCOS with insulin-focused care.
• Always use percent free PSA and velocity to decide on urology or MRI referral; MRI before biopsy is often acceptable and preferred.
• DHEA is a neurosteroid lever—especially useful for libido and mood when testosterone is adequate, but symptoms persist.
• Integrative chiropractic care improves the adherence ecosystem—the best endocrine plan still fails without daily execution.

References

• Ahmed, H. U., El-Shater Bosaily, A., Brown, L. C., Gabe, R., Kaplan, R., Parmar, M. K., … & Emberton, M. (2017). Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. The Lancet, 389(10071), 815–822.
• Arlt, W., Callies, F., van Vlijmen, J. C., Koehler, I., Reincke, M., Bidlingmaier, M., … & Allolio, B. (1999). Dehydroepiandrosterone replacement in women with adrenal insufficiency. New England Journal of Medicine, 341(14), 1013–1020.
• Carter, H. B., Pearson, J. D., Metter, E. J., Brant, L. J., Chan, D. W., Andres, R., … & Walsh, P. C. (1992). Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA, 267(16), 2215–2220.
• Catalona, W. J., Partin, A. W., Slawin, K. M., Brawer, M. K., Flanigan, R. C., Patel, A., … & Southwick, P. C. (1998). Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease. JAMA, 279(19), 1542–1547.
• Ding, E. L., Song, Y., Manson, J. E., Hunter, D. J., Lee, C. C., Rifai, N., … & Liu, S. (2009). Sex hormone–binding globulin and risk of type 2 diabetes in women and men. New England Journal of Medicine, 361(12), 1152–1163.
• Eskew, L. A., Bare, R. L., & McCullough, D. L. (1997). Multifactorial analysis of serum prostate-specific antigen velocity following definitive radiation therapy for localized prostate cancer. Urology, 50(4), 593–599.
• Goodarzi, M. O., Dumesic, D. A., Chazenbalk, G., & Azziz, R. (2011). Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nature Reviews Endocrinology, 7(4), 219–231.
• Hammond, G. L. (2016). Plasma steroid-binding proteins: primary gatekeepers of steroid hormone action. Journal of Endocrinology, 230(1), R13–R25.
• He, Y., & Shi, C. (2020). Gut microbiota and polycystic ovary syndrome: a novel therapeutic target. Journal of Translational Medicine, 18, 122.
• Jensterle, M., Salamun, V., Kocjan, T., Pfeifer, M., & Janez, A. (2015). Short-term administration of liraglutide leads to significant weight loss and improvement of cardiometabolic risk factors in obese women with PCOS. Hormone and Metabolic Research, 47(4), 275–279.
• Lakshman, K. M., Bhasin, S., Araujo, A. B., Travison, T. G., Williams, R. E., & Ellen, B. (2010). Measurement of sex steroid hormones in epidemiologic studies: better methods—better studies. Journal of Clinical Endocrinology & Metabolism, 95(10), 4543–4551.
• Landay, M., Huang, A., & Ng, E. (2009). OCPs in PCOS: a systematic review of randomized controlled trials comparing progestins. Fertility and Sterility, 92(2), 469–482.
• Lean, M. E. J., Leslie, W. S., Barnes, A. C., Brosnahan, N., Thom, G., McCombie, L., … & Taylor, R. (2019). Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results. Lancet Diabetes & Endocrinology, 7(5), 344–355.
• Loeb, S., Zhu, X., & Kan, D. (2007). Prostate-specific antigen velocity thresholds for predicting prostate cancer in young men. Journal of Urology, 177(3), 899–902.
• Maninger, N., Wolkowitz, O. M., Reus, V. I., Epel, E. S., & Mellon, S. H. (2009). Neurobiological and neuropsychiatric effects of dehydroepiandrosterone (DHEA) and DHEA sulfate (DHEAS). Frontiers in Neuroendocrinology, 30(1), 65–91.
• Morgentaler, A., & Traish, A. M. (2009). Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. European Urology, 55(2), 310–321.
• Pandit, S., Biswas, T. K., Debnath, P. K., & Ramaswamy, S. (2016). Clinical evaluation of purified Shilajit on testosterone levels in healthy volunteers. Andrologia, 48(5), 570–575.
• Podfigurna-Stopa, A., et al. (2016). Metformin in the treatment of polycystic ovary syndrome. Menopausal Review, 15(2), 85–90.
• Qi, X., Yun, C., Sun, L., Xia, J., Wu, Q., Wang, Y., … & Wang, G. (2019). Gut microbiota–bile acid–intestinal FXR axis orchestrates glucose and lipid homeostasis. EBioMedicine, 35, 178–190.
• Rainey, W. E., Rehman, K. S., & Carr, B. R. (2002). The human fetal adrenal cortex: differentiations and function. Endocrine Reviews, 23(4), 522–535.
• Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. (2004). Revised 2003 consensus on diagnostic criteria and long-term health risks related to PCOS. Human Reproduction, 19(1), 41–47.
• Selva, D. M., Hogeveen, K. N., Innis, S. M., & Hammond, G. L. (2007). Monosaccharide-induced lipogenesis regulates the human hepatic sex hormone–binding globulin gene. Journal of Clinical Investigation, 117(12), 3979–3987.
• Shufelt, C., Bretsky, P., Almeida, C. M., Johnson, B. D., Shaw, L. J., Azziz, R., … & Bairey Merz, C. N. (2010). DHEA-S levels and cardiovascular disease mortality in postmenopausal women. Journal of Clinical Endocrinology & Metabolism, 95(11), 4985–4992.
• Thompson, I. M., Pauler, D. K., Goodman, P. J., Tangen, C. M., Lucia, M. S., Parnes, H. L., … & Coltman, C. A. (2003). Prevalence of prostate cancer among men with a PSA level ≤4.0 ng per milliliter. New England Journal of Medicine, 349(4), 335–346.
• Thompson, I. M., et al. (2004). Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/mL or lower. JAMA, 291(3), 299–305.